Core Viewpoint - The company, Shanghai Rendu Biotechnology Co., Ltd., has announced its expected daily related transactions for the year 2026, which are deemed necessary for its daily operations and will not affect its independence or the interests of its shareholders [2][3][12]. Group 1: Daily Related Transactions - The expected daily related transactions for 2026 have been approved by the company's board of directors, with independent directors confirming that these transactions align with the company's operational needs and adhere to fair pricing principles [3][9]. - The estimated amount and categories of these transactions will be based on market prices and will not harm the interests of the company or its shareholders [4][10]. - The main content of the related transactions includes medical testing and reagent sales by the company's subsidiary to a related party, which is essential for the company's daily operations [7][9]. Group 2: Impact and Necessity of Related Transactions - The related transactions are necessary for the company's business development and are considered normal business activities that benefit both the company and its shareholders [9][10]. - The pricing of these transactions will follow fair and voluntary principles, ensuring that there is no detrimental impact on the company's operations or independence [10][11]. Group 3: Fund Management and Investment - The company plans to use up to RMB 390 million of temporarily idle funds for cash management, investing in safe and liquid financial products to enhance fund efficiency without affecting ongoing projects [38][42]. - The investment will be limited to a maximum of RMB 400 million in idle self-owned funds for purchasing financial products, ensuring that normal operations are not disrupted [62][69]. - The company will implement strict risk control measures and adhere to regulatory requirements to ensure the safety and efficiency of the funds used for investment [70][72].